Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03406806 Completed - Clinical trials for Validation of Gait Speed Device Against Existing Techniques

Gaitbox Validation Study

Start date: March 14, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to validate the walking velocity measured by the Gaitbox as compared to the measures obtained by clinicians administering the timed 4 meter walk test and the Sprint System device. The investigators have developed a compact device, the Gaitbox, which measures walking speed automatically. The device has an infrared light sensor that is capable to accurate distance measurements. To take a speed measurement, the device is placed at the end of the walking path and the subject simply walks towards the device. The device automatically records a starting and ending distance and calculates and displays walking speed in m/sec. This is a prospective, single site study. Up to 60 subjects will be enrolled at Duke. Subjects will be asked to complete the 4-meter walk test, three (3) times. Three speed measuring methods will be conducted simultaneously: NIH toolbox 4 meter clinic walk test and the Sprint System device (commercially available device typically used for timing track and field events), and the Gaitbox. The purpose is to validate the Gaitbox to the clinical NIH toolbox 4 meter test and against the Sprint System device. The following comparisons of speed will be made: Human timer 1 to human timer 2, Average human timer to Gaitbox, Gaitbox to Sprint System.

NCT ID: NCT03406520 Completed - Clinical trials for Peritoneal Dialysis Catheter Exit Site Infection

Chlorhexidine Disk for Prevention of Exit-site Infection in Peritoneal Dialysis Patients

Start date: March 7, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of chlorhexidine-impregnated disk in preventing catheter exit-site infection in peritoneal dialysis patients

NCT ID: NCT03406507 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Start date: February 22, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).

NCT ID: NCT03406468 Completed - Clinical trials for Non-Small Cell Carcinoma of Lung, TNM Stage 4

Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer

Start date: July 15, 2019
Phase: Phase 2
Study type: Interventional

Radiotherapy in combination with different forms of immune therapy improved consistently local tumor control and very interestingly, lead to better systemic tumor control and the induction of specific anti-cancer immunity with a memory effect. In small series, it has been shown that a new long-lasting remission can be induced by irradiating one tumor site in patients who showed cancer progression after an initial response to immune therapy. In these series, the original immune therapy was continued and the treatment was very well tolerated. In this study the progression-free survival after radiotherapy to a single lesion will be investigated in patients with stage IV non-small cell lung cancer (NSCLC), who have at least achieved stable disease with immune therapy alone or concurrent immune therapy and chemotherapy.

NCT ID: NCT03406429 Completed - Clinical trials for Non-Fluent Primary Progressive Aphasia

rTMS as a Treatment for PPA

Start date: December 1, 2019
Phase: Early Phase 1
Study type: Interventional

Primary progressive aphasia (PPA) includes three variants. Two such variants, the non-fluent/agrammatic variant (nfvPPA) and the logopenic variant (lvPPA), are characterized by progressive word-finding difficulties and effortful speech. Efforts to slow or halt this progression have been largely unsuccessful. As such, there is a desperate need for novel treatment strategies in PPA. Repetitive transcranial magnetic stimulation (rTMS) is a safe, non-invasive way of stimulating cortical targets in a focal and reproducible manner. Therapeutic benefits from rTMS have been demonstrated when it is applied in many sequential sessions. For example, repeated sessions of rTMS to left dorsolateral prefrontal cortex (dlPFC) is approved by the US Food and Drug administration as a treatment for major depressive disorder. With respect to language, high frequency rTMS increases the response rate for picture naming in healthy individuals. rTMS has also been shown to improve the number of correct naming responses in patients with Alzheimer's disease. Further, in a sham controlled study, Cotelli and colleagues demonstrated that in a group of 10 nfvPPA patients high frequency rTMS over the left and right dlPFC during object and action naming tasks improved the percent of correct responses for action, but not object naming. Finally, in a sham controlled single case study, Finocchiaro et al. applied high frequency rTMS to the left inferior mid-frontal gyrus for 3 sessions consisting of five consecutive days (treatment or sham). They found a significant and lasting improvement in the patient's performance on verb production when comparing active rTMS to sham rTMS or baseline. These studies have contributed valuable insights into the potential use of rTMS in treating the language symptoms of PPA patients.

NCT ID: NCT03406403 Completed - Clinical trials for LMA Versus Mgso4 in Attenuating Stress Response During Emergence of Supratentorial Tumours Patients

A Comparative Study Between Laryngeal Mask Airway and Magensium Sulphate in Attenuating Systemic Stress Response During Emergence of Patients Undergoing Supratentorial Tumours.

Start date: January 19, 2018
Phase: N/A
Study type: Interventional

To evaluate the efficacy of replacement of ETT with LMA and administration of Magnesium sulphate at the end of the surgery in attenuating systemic stress response during emergence of patients undergoing supratentorial tumours

NCT ID: NCT03406234 Completed - Metabolic Disease Clinical Trials

Observational Study on a Chinese Population

Start date: January 1, 2013
Phase: N/A
Study type: Observational

An observational study was conducted in a health examination center to distinguish risk factors for health in a randomly recruited volunteers of Chinese population.

NCT ID: NCT03406104 Completed - Clinical trials for Leber Hereditary Optic Neuropathy

RESCUE and REVERSE Long-term Follow-up

RESTORE
Start date: January 9, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4 mitochondrial mutation and who were treated in the Rescue or Reverse studies.

NCT ID: NCT03405467 Completed - Clinical trials for Cardiopulmonary Arrest With Successful Resuscitation

10-years Nationwide Alpine Accidents in Austria

Start date: January 21, 2015
Phase: N/A
Study type: Observational

This observational study intends to analyze the characteristic of specific accidents happened in Austrian's mountainous regions. The mechanisms of accidents which are evaluated are lightning accidents, cardiopulmonary resuscitation with or without automated external defibrillator, frostbite injuries, accidents with flying vehicle (e.g. paraglider, hang-glider…).

NCT ID: NCT03405415 Completed - Clinical trials for Subjects Without Diabetes Mellitus

Assessment of Glucose Concentrations in People Without Diabetes Mellitus After Standardized Meals and in Daily Life

Start date: January 27, 2018
Phase: N/A
Study type: Interventional

Participants will perform blood glucose monitoring (BGM) over the course of 14 days and, in parallel, wear continuous glucose monitoring (CGM) systems. Because current CGM systems typically achieve a lower level of analytical accuracy than BGM systems, participants will perform at least 5 blood glucose (BG) measurements per day. In addition, CGM systems are used to obtain minimally-invasive high-frequency glucose measurements to fill the gaps between BG measurements.